Advanced Cancer Nanotheranostics

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".

Deadline for manuscript submissions: closed (20 October 2023) | Viewed by 4145

Special Issue Editor


E-Mail Website
Guest Editor
Nanobiotechnology for Life Sciences Group, Department of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, E-28040 Madrid, Spain
Interests: nanobiotechnology; medicinal chemistry; multimodal molecular imaging; theranosis; nanoparticles; cancer; kidney and cardiovascular diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is still a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Thanks to medical progress, the available therapeutic and diagnostic possibilities have increased notably in recent years. However, it is now clear that both strategies suffer from some intrinsic limitations that impact on the whole cancer management. In fact, an optimized cancer therapy should ideally deliver the right therapy, to the right target, in a controlled fashion and with minimal systemic toxicity. Furthermore, this task appears more daunting if we consider that, in cancer, the careful coordination of diagnosis and therapy is mandatory in order to finely evaluate and calibrate the applied therapies.

Nanotechnology has emerged as a powerful strategy to overcome these limitations and, in recent decades, has promoted the production of a wide set of nanoplatforms with multifunctional abilities for tumor targeting, drug loading, and controlled release. Furthermore, imaging functionalities have been coupled to these nanoplatforms, thus enabling the possibility to also diagnose cancer and monitor therapeutic progression non-invasively and in real time. Such a fusion of therapy and diagnosis promoted by nanostructured materials is known as ‘nanotheranostics’, and these multifunctional nanotools have encountered a great applicability in biomedicine and especially in the medical management of a lot of cancers.

This Special Issue will highlight the current state of the art in the exciting and highly promising area of cancer nanotheranosis.

Prof. Dr. Marco Filice
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • theranostics
  • nanotechnology
  • cancer
  • nanomedicine
  • multifunctional nanoparticle
  • multimodal molecular imaging
  • drug delivery
  • drug targeting
  • combined cancer therapy
  • clinical trials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

25 pages, 2757 KiB  
Article
Towards Cancer Nanoradiopharmaceuticals—Radioisotope Nanocarrier System for Prostate Cancer Theranostics Based on Radiation-Synthesized Polymer Nanogels
by Beata Paulina Rurarz, Kinga Anna Urbanek, Urszula Karczmarczyk, Joanna Raczkowska, Dominika Ewa Habrowska-Górczyńska, Marta Justyna Kozieł, Karolina Kowalska, Sławomir Kadłubowski, Agnieszka Sawicka, Michał Maurin, Agnieszka Wanda Piastowska-Ciesielska and Piotr Ulański
Cancers 2023, 15(23), 5646; https://doi.org/10.3390/cancers15235646 - 29 Nov 2023
Cited by 1 | Viewed by 1580
Abstract
Despite the tremendous development of oncology, prostate cancer remains a debilitating malignancy. One of the most promising approaches to addressing this issue is to exploit the advancements of nanomedicine in combination with well-established nuclear medicine and radiotherapy. Following this idea, we have developed [...] Read more.
Despite the tremendous development of oncology, prostate cancer remains a debilitating malignancy. One of the most promising approaches to addressing this issue is to exploit the advancements of nanomedicine in combination with well-established nuclear medicine and radiotherapy. Following this idea, we have developed a radioisotope nanocarrier platform of electron-beam-synthesized nanogels based on poly(acrylic acid). We have developed a functionalization protocol, showing the very high (>97%) efficiency of the conjugation in targeting a ligand–bombesin derivative. This engineered peptide can bind gastrin-releasing peptide receptors overexpressed in prostate cancer cells; moreover, it bears a radioisotope-chelating moiety. Our nanoplatform exhibits very promising performance in vitro; the radiolabeled nanocarriers maintained high radiochemical purity of >90% in both the labeling buffer and human serum for up to 14 days. The application of the targeted nanocarrier allowed also effective and specific uptake in PC-3 prostate cancer cells, up to almost 30% after 4 h, which is a statistically significant improvement in comparison to carrier-free radiolabeled peptides. Although our system requires further studies for more promising results in vivo, our study represents a vital advancement in radionanomedicine—one of many steps that will lead to effective therapy for castration-resistant prostate cancer. Full article
(This article belongs to the Special Issue Advanced Cancer Nanotheranostics)
Show Figures

Graphical abstract

14 pages, 2037 KiB  
Article
Enhancement of Tumor Cell Immunogenicity and Antitumor Properties Derived from Platinum-Conjugated Iron Nanoparticles
by Ángela-Patricia Hernández, Laura Iglesias-Anciones, José Javier Vaquero-González, Rafael Piñol, Julio J. Criado, Emilio Rodriguez, Pablo Juanes-Velasco, Marina L. García-Vaquero, Carlota Arias-Hidalgo, Alberto Orfao, Ángel Millán and Manuel Fuentes
Cancers 2023, 15(12), 3204; https://doi.org/10.3390/cancers15123204 - 15 Jun 2023
Cited by 4 | Viewed by 1783
Abstract
From chemistry design to clinical application, several approaches have been developed to overcome platinum drawbacks in antitumoral therapies. An in-depth understanding of intracellular signaling may hold the key to the relationship of both conventional drugs and nanoparticles. Within these strategies, first, nanotechnology has [...] Read more.
From chemistry design to clinical application, several approaches have been developed to overcome platinum drawbacks in antitumoral therapies. An in-depth understanding of intracellular signaling may hold the key to the relationship of both conventional drugs and nanoparticles. Within these strategies, first, nanotechnology has become an essential tool in oncotherapy, improving biopharmaceutical properties and providing new immunomodulatory profiles to conventional drugs mediated by activation of endoplasmic reticulum (ER) stress. Secondly, functional proteomics techniques based on microarrays have proven to be a successful method for high throughput screening of proteins and profiling of biomolecule mechanisms of action. Here, we conducted a systematic characterization of the antitumor profile of a platinum compound conjugated with iron oxide nanoparticles (IONPs). As a result of the nano-conjugation, cytotoxic and proteomics profiles revealed a significant improvement in the antitumor properties of the starting material, providing selectivity in certain tumor cell lines tested. Moreover, cell death patterns associated with immunogenic cell death (ICD) response have also been identified when ER signaling pathways have been triggered. The evaluation in several tumor cell lines and the analysis by functional proteomics techniques have shown novel perspectives on the design of new cisplatin-derived conjugates, the high value of IONPs as drug delivery systems and ICD as a rewarding approach for targeted oncotherapy and onco-immunotherapies. Full article
(This article belongs to the Special Issue Advanced Cancer Nanotheranostics)
Show Figures

Figure 1

Back to TopTop